NKGen Biotech (NKGN) Stock Price, News & Analysis

Company Overview

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Key Stats

• Today's Range: $0.11 to $0.12
• 50-Day Range: $0.11 to $0.28
• 52-Week Range: $0.10 to $0.96
• Volume: 2,101 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $4.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NKGen Biotech Stock Analysis - MarketRank™

NKGen Biotech scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NKGen Biotech.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NKGen Biotech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NKGen Biotech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.86% of the float of NKGen Biotech has been sold short.

Short Interest Ratio / Days to Cover

NKGen Biotech has a short interest ratio ("days to cover") of 80.5, which indicates bearish sentiment.

Change versus previous month

Short interest in NKGen Biotech has recently decreased by 0.08%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NKGen Biotech does not currently pay a dividend.

Dividend Growth

NKGen Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.86% of the float of NKGen Biotech has been sold short.

Short Interest Ratio / Days to Cover

NKGen Biotech has a short interest ratio ("days to cover") of 80.5, which indicates bearish sentiment.

Change versus previous month

Short interest in NKGen Biotech has recently decreased by 0.08%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for NKGen Biotech this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NKGen Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.36% of the stock of NKGen Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.17% of the stock of NKGen Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NKGN Stock Analysis - Frequently Asked Questions

How have NKGN shares performed this year?

NKGen Biotech's stock was trading at $0.6552 on January 1st, 2025. Since then, NKGN stock has decreased by 83.2% and is now trading at $0.11.

How do I buy shares of NKGen Biotech?

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NKGen Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI).

Company Calendar

• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NKGN
• Previous Symbol: NYSE:NKGN
• CIK: 1845459
• Web: nkgenbiotech.com
• Phone: 949-396-6830
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -479.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.68) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 44,948,000
• Free Float: 40,291,000
• Market Cap: $4.94 million
• Optionable: Not Optionable
• Beta: 1.19